跳至主要内容

Medicilon helps Sungening Biological's first innovative drug SG1001 oral tablet obtain IND approval in China

Recently, Sungening Biological's (Sungening) first innovative drug SG1001 successfully obtained the implicit clinical trial approval from the National Medical Products Administration (Acceptance Number: CXHL2400203).  The approved indication is invasive fungal disease (IFD), and clinical trials are about to begin.  This milestone progress not only marks Sungening’s official entry into the ranks of clinical-stage innovative drug companies, but also promotes China’s drug innovation process in the field of antifungal infections.



Shanghai Medicilon Inc. (Medicilon), as a partner of Sungening Biological, relies on its technical strength and rich experience in the field of biopharmaceutical preclinical research and development to provide pharmacokinetics and GLP safety evaluation research services for the research and development of SG1001, and fully ensures its efficient and high-quality research and development.

The success of every R&D collaboration is the accumulation and improvement of Medicilon's professional knowledge and skills, and it also lays a solid foundation for Medicilon to provide more efficient services in the future.  Sungening's SG1001 has obtained clinical trial approval, which is undoubtedly another affirmation of the professional strength and excellent service of Medicilon's preclinical research service platform, and also adds another important success story to the platform.

Currently, Medicilon's preclinical research service platform has a laboratory of 29,000 square meters, has obtained the NMPA GLP laboratory certification qualification, and has established a research operation process and quality system that complies with international standards.  Medicilon complies with the GLP laboratory standards of the US FDA, Australian TGA, and EU EMA; the animal experimental facilities have passed the International Laboratory Animal Assessment and Accreditation (AAALAC) and the non-human primates, dogs, mice, rabbits, guinea pigs, mini pigs and other experimental animals can be raised at the same time.  Complete and professional facilities provide Medicilon with strong support for pharmacological efficacy, pharmacokinetic research and safety evaluation services, ensuring the accuracy and reliability of experimental results.

About Sungening Biological

Founded in 2021, Sungening Biological is an innovative drug company focusing on innovative antifungal infection drugs and oral cyclic peptides. Sungening Biological also has a complete independently developed drug pipeline and mature commercialization capabilities.  With the vision of "focusing on the research and development of new drugs to solve clinical needs and protecting human health", Sungening Biological strives to develop innovative drugs that can fulfill clinical needs.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...